Liposome formulations of o-carborane for the boron neutron capture therapy of cancer

Temidayo O.B. Olusanya, Gianpiero Calabrese, Dimitrios G. Fatouros, John Tsibouklis, James R. Smith
  • Biophysical Chemistry, February 2019, Elsevier
  • DOI: 10.1016/j.bpc.2019.01.003

Liposome formulation to deliver boron compounds for cancer treatment

Photo by Michael Longmire on Unsplash

Photo by Michael Longmire on Unsplash

What is it about?

Boron Neutron Capture Therapy (BNCT) is a type of radiotherapy where boron-containing compounds are preferentially uptaken by tumour cells and then the area is exposed to a low energy neutron beam (much less damaging than radiotherapy). This causes the boron, located in the cancer cells, to emit a radioactive alpha particle which destroys the cancer cells. Since the alpha particles can only travel about one cell's distance from the boron-containing cancer cells, surrounding normal tissue is unaffected. This paper describes the formulation and stability of nanoparticles, known as liposomes, containing the model boron-containing material, ortho carborane.

Why is it important?

Formulating stable and effective boron-containing compounds is important in the development of Boron Neutron Capture Therapy for treating cancer.

Perspectives

Dr James R Smith
University of Portsmouth

A free download of the paper (postprint version) is available from the resources section (right-hand-side panel).

Read Publication

http://dx.doi.org/10.1016/j.bpc.2019.01.003

The following have contributed to this page: Dr James R Smith